drugset / Trial / NCT04220684
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Natural killer cells are a type of immune cell. Immunotherapy with genetically modified NK cells from donors may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread.
Timeline
- Start
- 2020-06-11
- Primary completion
- 2024-10-22
- Completion
- 2024-10-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 2 g | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Subject | KDS-1001 | Cell therapy | — | — |